SuperOxide Health Sciences

SuperOxide Health Sciences is a biotechnology company focused on developing a new class of catalytic antioxidant therapies to treat inflammatory and fibrotic diseases. The company's core technology centers on superoxide dismutase (SOD) mimetics, which are small molecules designed to mimic the activity of the natural SOD enzyme to neutralize reactive oxygen species. Their lead candidate, SO-001, is being investigated for the treatment of idiopathic pulmonary fibrosis (IPF) and radiation-induced lung injury. By reducing oxidative stress and preventing tissue damage, the company aims to provide transformative treatments for conditions with high unmet medical needs. The company's research is rooted in decades of expertise in redox biology and metalloporphyrin chemistry.